## CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>FOREWORD FROM THE PRESIDENT</td>
<td>3</td>
</tr>
<tr>
<td>SNAPSHOTS 2017</td>
<td>4</td>
</tr>
<tr>
<td>ABOUT FIP</td>
<td>8</td>
</tr>
<tr>
<td>MEMBERSHIP</td>
<td>10</td>
</tr>
<tr>
<td>VIGNETTES 2017</td>
<td>12</td>
</tr>
<tr>
<td>Focus on our profession and practice</td>
<td>12</td>
</tr>
<tr>
<td>Health benefits for our communities</td>
<td>14</td>
</tr>
<tr>
<td>Education and human resources</td>
<td>16</td>
</tr>
<tr>
<td>Collaborations and partnerships</td>
<td>18</td>
</tr>
<tr>
<td>WORLD PHARMACISTS DAY</td>
<td>20</td>
</tr>
<tr>
<td>6TH PHARMACEUTICAL SCIENCES WORLD CONGRESS</td>
<td>21</td>
</tr>
<tr>
<td>AWARDS</td>
<td>22</td>
</tr>
<tr>
<td>ELECTIONS AND COUNCIL DECISIONS</td>
<td>24</td>
</tr>
<tr>
<td>77TH WORLD CONGRESS OF PHARMACY AND</td>
<td>25</td>
</tr>
<tr>
<td>PHARMACEUTICAL SCIENCES</td>
<td></td>
</tr>
<tr>
<td>PUBLICATIONS</td>
<td>26</td>
</tr>
<tr>
<td>WORK IN PROGRESS</td>
<td>27</td>
</tr>
<tr>
<td>FINANCES</td>
<td>30</td>
</tr>
</tbody>
</table>
I would like, first of all, to extend a big thank you to all those who gave so generously of their time last year to represent FIP around the world, to contribute to our publications and policy work, and to partner with us, all in the service of global health. Through our diverse work, which is highlighted in the pages of this annual report, the importance of pharmaceutical educators, pharmaceutical scientists and pharmacists in achieving health and well-being for all is resoundingly clear. Universal health coverage demands a competent and sufficient in number healthcare workforce, quality medicines, access to and responsible use of those medicines, and health systems that are efficient, equitable and sustainable. In 2017, we made more steps towards these goals through our three main areas of work: education, science and practice.

FIP Education has continued with efforts towards our Global Vision for Education and Workforce, with the development of resources to support the implementation of this vision. I am very proud that our federation is now regarded internationally as a pioneer among the healthcare professions for its work in this important area, and is being invited by health ministers to share our experience and tools (see p16).

Pharmaceutical science is key to ensuring better medicines, and this was highlighted through the theme of the Sixth World Congress of Pharmaceutical Sciences, held in May. It was a privilege to see over 1,000 scientists from 73 countries brought together, under the umbrella of FIP, in the name of “Future medicines for one world” (see p21).

And then, at the frontline are my fellow pharmacists, who strive daily to serve through promoting good health and ensuring that each and every patient gets the right medicine, at the right dose, at the right time. At FIP, we have been aiding their efforts through our reports and policy work, which last year included harm reduction, medicines information, self care, disaster management and antimicrobial resistance. Surely, this work provides the foundations for advancing our profession and supporting the development of the services and systems that our patients need.

I continue to be heartened and inspired by my colleagues, and was particularly so at the 2017 World Congress of Pharmacy and Pharmaceutical Sciences. At this meeting, where 2,000 people gathered from around the world, the very essence of pharmacy — its “soul” (see p25) — was evident. Moreover, the theme of the congress “Medicines and beyond” highlighted that pharmacy is not only about medicines, it’s about people, services and sustainability. I look forward to this year’s congress, which will be held in Glasgow, UK, under the exciting banner of “transforming outcomes”.

The 2017 World Pharmacists Day slogan, “From research to health care: Your pharmacist is at your service,” neatly encapsulates all I have said so far, and the many activities held around the world to mark this special day (see p20) demonstrate that service is a strong conviction within our profession.

Through our efforts — and our worldwide network of experts and national member organisations — we have made many achievements and will continue to do so. Let us be in no doubt that the pharmacy profession has a firm place in the universal health coverage agenda. It is through working together in the service of global pharmacy that, ultimately, we serve global health.

Carmen Peña

President

International Pharmaceutical Federation (FIP)
TACKLING DEMENTIA WITH SCIENCE AND PRACTICE

We called on governments to increase investment in pharmaceutical sciences related to dementia research. At the 140th World Health Organization Executive Board meeting in Geneva, Switzerland, we described pharmacists’ technical expertise in dementia and explained how they are well placed to lead and be co-organisers of awareness campaigns, screening activities and community-based dementia partnership programmes. Dementia was among seven topics that FIP made statements on at the meeting:

- Antimicrobial resistance
- Cancer prevention and control
- Dementia
- Global Vaccine Action Plan
- Human resources for health
- Shortages of medicines and vaccines
- Substandard/counterfeit medical products

(on behalf of the World Health Professions Alliance)

ADVOCATING PATIENT-CENTRED POLICIES

Patients should be empowered with a more active role to achieve the best treatment results and health systems should adapt to patients’ needs, rather than patients adapting to the system, FIP President Carmen Peña told delegates at Oman’s Seventh Pharmaceutical Care Conference, organised by the country’s Ministry of Health Directorate General of Medical Supplies, where she was key speaker. Dr Peña was welcomed by the health minister, who listened to her talk about pharmacists of the 21st century. Our President made clear that part of catering for the new patient profile is to focus on services because people need them. While in Muscat, Dr Peña also led a meeting with the presidents of the national associations of pharmacists of Bahrain, Oman, United Arab Emirates and Saudi Arabia, further expanding our outreach in the Eastern Mediterranean region.

SHAPING EDUCATION IN ANTIMICROBIAL RESISTANCE

FIP has long been an important partner to the World Health Organization, especially when it comes to the topic of antimicrobial resistance (AMR). We continued with this work, being one of the expert bodies that the WHO consulted on resources and requirements for health worker education around AMR, particularly around effective antibiotic stewardship. As a result, a competency framework for AMR control and an outline for developing pre-service and in-service AMR educational curricula are among a list of tools to be developed in light of the latest evidence, followed by a comprehensive strategy to disseminate these tools. FIP will be a reviewer of the competency framework, which will guide governments on the competency levels for effective antibiotic stewardship.
HELPING PEOPLE TO HELP THEMSELVES
Community pharmacies have, for decades, provided care through giving advice, supplying medicines or, when needed, referring patients to other healthcare professionals. However, a formalised approach whereby pharmacies are reimbursed for these services is now being embedded in many countries. We believe that self-care through pharmacists should be considered as an integral part of the health system and we communicated this through the launch of our report “Pharmacy as a gateway to care: Helping people towards better health”. This report gives examples from around the world of the recognition of pharmacies as a formal first point of access to healthcare systems. Subsequently, in September, the FIP Council adopted a new policy statement on self care (see p24).

HIGHLIGHTING HARM REDUCTION VALUE
That pharmacists are at the forefront of a number of services to reduce drug-related harm was highlighted to the 70th World Health Assembly in Geneva, Switzerland, when the public health dimension of the world drug problem was discussed. We gave health ministers examples from around the world, including needle exchange programmes, opioid substitution therapy and educational campaigns. (This work was followed in November with the publication of a report “Reducing harm associated with drugs of abuse: The role of pharmacists” from FIP’s specialist working group — see p26). Harm reduction was among five areas on which FIP made statements:
- Antimicrobial resistance
- Global shortage of medicines and vaccines
- Human resources for health
  (plus a second statement on behalf of the World Health Professions Alliance)
- Non-communicable diseases — prevention and control
- World drug problem – public health

SUPPORTING ACCESS TO ESSENTIAL MEDICINES
FIP is the only non-governmental organisation that is invited to participate at Interagency Pharmaceutical Coordination group meetings, where pharmaceutical policies developed by United Nations agencies and programmes are discussed. At the meeting in June, held in Geneva, Switzerland, the focus was on stimulating the local production of essential medicines to serve national and, possibly, neighbouring markets. At this meeting, we asserted the need to develop a competent workforce of industrial as well as humanitarian pharmacists to implement this goal and discussed collaboration on the development of a competency framework for these pharmacists as well as those working in medicines regulation.
SERVING FUTURE HEALTH
The views of pharmacists were brought to a Europe-wide discussion of scenarios for the future of health care by our professional secretary Ema Paulino at the Health Futures Forum in Leuven, Belgium, organised by the think tank European Health Forum Gastein. Participants linked to governments, patient and consumer organisations and public health organisations explored what health policy choices will need to be made in the next 20 years and we were there to ensure that pharmacists were considered as part of the solution for the envisioned challenges.

LOOKING OUT FOR PATIENTS
Interventions to address medication errors was a particular focus in August. Our work on patient safety continued, with input into three technical reports representing the “flagship” elements of the World Health Organization’s third Global Patient Safety Challenge “Medication without harm”. We had already supported the launch of the challenge in March at the ministerial summit on patient safety in Bonn, Germany, and were pleased to lend our expertise to the technical reports on (i) medication safety in high risk situations, (ii) appropriate polypharmacy, and (iii) transitions of care, which were finalised in August.

REFOCUSING FOR OUR MEMBERS
We want to ensure that our federation is better able to respond effectively to our members’ needs and more actively support the evolution of science, practice and education. With this objective, work on a new strategic plan officially started in September with a consultation of FIP Council members on a new vision and mission. Questions were also put to the wider profession through a survey with the findings presented to our Strategic Planning Committee and the FIP Bureau for taking the work forward.
TALKING NATIONAL PLANS
Challenges of an elderly society and building a full range of drug care were topics discussed between our President Carmen Peña and Taiwan’s President Tsai Ing-Wen. During the meeting in China Taiwan, President Tsai told Dr Peña that pharmacists are indispensable to the healthcare system and that over the past year, the government had worked to establish standard operating procedures to improve the professional services of pharmacists. In particular, it sees a strong role for pharmacists in preventing waste of medical resources and ensuring medicines safety. Our presence in China Taiwan served to garner government commitment for our Taiwanese colleagues.

BUILDING THE HEALTH WORKFORCE
Our focus on creating a fit-for-purpose future health workforce progressed with our signing of two key global documents at the Fourth Forum on Human Resources for Health in Dublin, Ireland. The first, known as the Dublin Declaration, sets out actions to prevent the projected shortfall of 18 million health workers. Our contribution to the drafting work helped to ensure that the policy paper “Transforming and scaling up health professionals’ education and training: WHO Education Guidelines 2013” was taken into account. The second document was a call for action for the commitment of youth to the human resources for health agenda to achieve better health for all and to support the path to universal health coverage. During the forum, we also accepted an invitation to become a member of the Gender Equity Hub (part of the WHO global health workforce network) so that we can increase the reach of our current work to empower women and progress the implementation of Pharmaceutical Workforce Development Goal 10 — Gender and Diversity Balances.

SPREADING INNOVATIONS
FIP prides itself on bringing people together and enabling a truly global network. We do this so that colleagues can share and learn from news and from the experiences of others around the world in order to advance the profession through developments in science, practice and education. One such example is our spreading the news of team-based learning being incorporated into the pharmacy curriculum in South Africa through a video interview. This video is one of a long series covering numerous topics from a new Pharmacy White Paper in Norway to a model of care where pharmacists work in general practitioner practices in the UK.
WHO WE ARE
The International Pharmaceutical Federation (FIP) is the global federation of national associations of pharmacists and pharmaceutical scientists. With 140 member organisations, we represent more than four million experts in medicines. FIP is a non-governmental organisation that has been in official relations with the World Health Organization since 1948. Through our partnerships and our extensive global pharmacy and pharmaceutical sciences network, we work to support the development of the pharmacy profession, through practice and emerging scientific innovations, in order to meet the world’s health care needs.

WHAT WE DO — VISION AND MISSION
Our strategy (“2020 Vision”) is to ensure that FIP is an integral participant in global health care decisions and actions. As such, the vision that FIP holds is that wherever and whenever decision-makers discuss any aspects of medicines at a global level, FIP is at the table.

FIP is enabled to succeed in this vision through the recognition and respect it gains in the fulfilment of its mission, which is to improve global health by advancing pharmaceutical education, sciences and practice, thus encouraging, promoting and enabling better discovery, development, access to and responsible use of appropriate, cost-effective, quality medicines worldwide.

Molecules only become medicines when pharmaceutical expertise is added. Pharmacists, through ensuring their responsible use, optimise the effects of these medicines. Examples of what we do and the impact of our work can be found throughout the pages of this annual report.

HOW WE WORK — STRUCTURE
FIP’s activities can be divided into three main areas — science, practice and education — although there is increasing collaboration between these areas.

One of our objectives is to advance the pharmaceutical sciences and this is primarily done through the work of nine special interest groups (SIGs) led by the Board of Pharmaceutical Sciences. There are SIGs for:
- Analytical sciences and pharmaceutical quality
- Biotechnology
- Drug design and discovery
- Formulation design and pharmaceutical technology
- Natural products
- Pharmacokinetics, pharmacodynamics and systems pharmacology
- Pharmacy practice research
- Regulatory sciences
- Translational research and precision medicine

Another of our objectives is to advance pharmacy practice in all settings, and this is done through the projects and initiatives of eight pharmacy practice sections. There are sections for:
- Academic pharmacy
- Clinical biology
- Community pharmacy
- Health and medicines information
- Hospital pharmacy
- Industrial pharmacy
- Military and emergency pharmacy
- Social and administrative pharmacy

The reform of pharmacy and pharmaceutical sciences education in the context of pharmaceutical workforce development is a third objective and this is the purpose of FIP Education (FIPEd), which includes an academic institutional membership (deans of schools of pharmacy and
FIP's day-to-day activities are managed by an executive committee and a team of staff at our headquarters in the Netherlands.

FIP is governed by a Council and Bureau (board). The Council is FIP's highest administrative organ and all member organisations have voting rights (Our observer organisations participate in the Council but cannot vote) The Council also includes representatives from the FIP sections and the Bureau. The Bureau consists of 16 elected officers (plus the FIP chief executive officer, ex officio) as follows:

- **President**
  Dr Carmen Peña (Spain)

- **Chief executive officer**
  Mr Luc Besaçon (Netherlands) — until 31 October 2017 (followed by Ms Ema Paulino (Portugal), from 1 November 2017, as interim CEO)

- **Immediate past president**
  Dr Michel Buchmann (Switzerland)

- **Scientific secretary**
  Prof. Giovanni Pauletti (USA)

- **Professional secretary**
  Ms Ema Paulino (Portugal)

- **Chair of FIP Education**
  Prof. William Charman (Australia)

- **Chair of the Board of Pharmaceutical Sciences**
  Prof. Tatsuro Irimura (Japan)

- **Chair of the Board of Pharmaceutical Practice**
  Mr Dominique Jordan (Switzerland)

- **Nine vice presidents**
  Mr Andrew L. Gray (South Africa)
  Dr Linda Hakes (UK)
  Prof. Ross McKinnon (Australia)
  Mr Tom Menighan (USA)
  Dr Eduardo Savio (Uruguay)
  Prof. Philip J. Schneider (USA)
  Ms Jacqueline Surugue (France)
  Ms Eeva Teräsalmi (Finland)
  Mr Nobuo Yamamoto (Japan)
FIP MEMBERSHIP

THROUGH OUR MEMBERSHIP, FIP HAS PRESENCE IN 152 COUNTRIES AND TERRITORIES. THIS COVERS OVER 7.4 BILLION PEOPLE.
NEW MEMBER ORGANISATIONS
At its meeting in August 2017, the FIP Council admitted five new member organisations:

- Order of Pharmacists of Cabo Verde
- Canadian Society for Pharmaceutical Sciences
- Fiji Pharmaceutical Society
- Hong Kong Pharmacists Union
- Rwanda Community Pharmacists Union

A full list of FIP member organisations can be found at http://bit.ly/2JnWHyx.

NEW ACADEMIC INSTITUTIONAL MEMBERS
FIP welcomed the following schools of pharmacy as academic institutional members in 2017:

- Ajou University (Republic of Korea)
- Autonomous University of Coahuila (Mexico)
- The Chinese University of Hong Kong (Hong Kong, China)
- The Hashemite University (Jordan)
- Howard University (United States of America)
- Islam University Indonesia (Indonesia)
- Jenderal Achmad Yani University (Indonesia)
- Medical University of Varna (Bulgaria)
- Oman Assistant Pharmacy Institute, Ministry of Health (Oman)
- The Pacific University Oregon (United States of America)
- RMIT University (Australia)
- Sofia University “St. Kliment Ohridski” (Bulgaria)
- University of Otago (New Zealand)
- University of Sharjah (United Arab Emirates)

A full list of FIP academic institutional members can be found at: http://bit.ly/2qaQayA.

NEW OBSERVER ORGANISATION
At its meeting in August 2017, the FIP Council admitted the Directorate General of Medical Supplies, Ministry of Oman, as a new observer organisation.

A full list of FIP observer organisations can be found at: http://bit.ly/2JpYQcT.

Mr Flandrie Habyarimana, president, Rwanda Community Pharmacists Union

"By joining FIP, pharmacy professionals will get the opportunity to share innovations, keep up to date and work in close collaboration with their colleagues from around the world."

Ms Sara Albalushi, director, Pharmaceutical Care Department, Directorate General of Medical Supplies, Oman Ministry of Health

"The Directorate General of Medical Supplies joined FIP to be updated regarding the practice of pharmacy globally, and to work on advancing pharmaceutical care within Oman’s Ministry of Health with information from FIP working groups. We also hope to benefit from future FIP projects."

Dr Saja Hamed, dean, Hashemite University, Jordan

"We became an academic institutional member to share with FIP members our own experience in improving pharmacy education and mutually get introduced to other successful experiences all around the world. We were the first faculty of pharmacy from Jordan to join FIP academic institutional membership, and I would recommend all faculties of pharmacy who are not yet members to apply. I attended the Deans Forum in Seoul. It was a unique experience that enriched my knowledge and introduced me to many leaders in pharmacy education all over the world."
FOCUS ON OUR PROFESSION AND PRACTICE

STANDING UP FOR PROFESSIONAL AUTONOMY

Pharmacists should be free to exercise their professional judgement in patient care, regardless of the economic or business model of practice, FIP interim CEO and professional secretary Ema Paulino told an audience of health professionals, regulators and policymakers in November. Ms Paulino was a guest panellist and moderator at a discussion about how regulation can ensure quality health care, professional autonomy and protection of the public’s interest, during a side event at a Global Forum on Human Resources for Health in Dublin, Ireland, which was jointly organised by FIP and the World Medical Association. Another concern raised by FIP at the session was the growing commercialisation of health care.

Dr Julia Tainijoki-Seyer, medical adviser and UN representative, World Medical Association

“Professional autonomy is important for fulfilling the healthcare professional’s societal mandate for quality and ethical care. It is key to achieving universal health coverage and implementing the Global Strategy on Human Resources for Health. It was valuable to work alongside pharmacists in order to get these points across to regulators and policymakers from the public and private sectors.”

PROMOTING PHARMACEUTICAL SCIENCE

A number of our officers generously give their time to act as ambassadors for FIP, global pharmacy, pharmaceutical sciences and education. One example is the attendance of our Board of Pharmaceutical Sciences chair Tatsuro Irimura at the annual conference of the Chinese Pharmaceutical Association (CPA). Professor Irimura was a key speaker at the conference, held in Xi’an in November, which also marked the CPA’s 100th anniversary. During his visit, Professor Irimura took the opportunity to meet with Vice Minister Xianze Sun of the China Food and Drug Administration, who expressed a “strong desire” for advancing science and technology for drug development, and for increased involvement with FIP activity.

Mr Michael Anisfeld, president, FIP Industrial Pharmacy Section

“The GMP workshop provided a unique opportunity to exchange knowledge and ideas, to discuss future development, present experience and explore opportunities for international collaboration. In this way the section contributed to raising professional standards and, in the long term, to advancing pharmacy practice.”

SHARING GOOD MANUFACTURING PRACTICE

The practice of ensuring that medicines are produced to a consistently high quality — good manufacturing practice (GMP) — was given a boost by FIP’s Industrial Pharmacy Section in September. Three of the section’s executive committee members were the main invited speakers at a GMP workshop held in Seoul, Republic of Korea, by the Korean Society of Pharmaceutical Sciences and Technology, sharing their experiences of quality-by-design-based GMP inspection and registration of advanced formulations.

Mr Michael Anisfeld, president, FIP Industrial Pharmacy Section

“The GMP workshop provided a unique opportunity to exchange knowledge and ideas, to discuss future development, present experience and explore opportunities for international collaboration. In this way the section contributed to raising professional standards and, in the long term, to advancing pharmacy practice.”
PROVIDING TOOLS FOR ADVOCACY

The clear contribution of pharmacy to health beyond dispensing is underlined by the findings of our latest biennial global pharmacy survey published in September. The findings were published in two reports, “Pharmacy at a glance: 2015–2017” (a publicly accessible summary of the survey) and “Pharmacy: A global overview — Workforce, medicines distribution, practice, regulation and remuneration 2017” (an in-depth, 300-page report produced exclusively for our member organisations). The report contains a wide range of information, including that a number of advanced community pharmacy services are now offered in countries and territories covering over three-quarters of the world’s population. For anyone wishing to create change and advance the profession, another report published in 2017 was our Board of Pharmaceutical Practice’s “Pharmacy vision”, which presents trends in practice as forecast by each of FIP’s sections, from community and hospital pharmacy to industrial and military and emergency practice. For each practice area the document outlines clear objectives and tasks according to the needs of the profession.

Ms Isabel Reinoso, president, Argentinian Pharmaceutical Confederation

“Pharmacy: A global overview” was an inspirational report highlighting the growing implementation of professional services by pharmacists around the world. It was also interesting to learn, through this pharmacy atlas, how pharmacy is practised in the different regions, each with its own characteristics. We published a summary of the report in our journal, and also disseminated it through our social networks and we will surely be using the statistical information that emerged from the survey in our own documents and presentations, to understand the situation of pharmacy in Argentina within the international context.”

SUPPORTING UNITY

We were pleased to be able to support the first Brazilian Congress of Pharmaceutical Sciences, held in Parana by the Brazilian Federal Council of Pharmacy in November, with the attendance of our President Carmen Peña. Speaking to an audience of pharmacists and pharmacy students, Dr Peña focused on the needs for professional development through education and for promoting and defending the interests of pharmacy as an integral part of health care. She also met with Brazil’s Minister of Health Ricardo Barros during her visit, and emphasised to him that pharmaceutical services are an intrinsic part of health services and that encouraging and investing in the creation of new health worker jobs is one of the best ways to achieve universal health coverage.

Dr Walter da Silva João, president, Federal Council of Pharmacy of Brazil

“Carmen Peña has always paid close attention to the countries of South America, seeking solutions and participating in important strategic discussions for the region. Representing the largest pharmaceutical organisation worldwide, Dr Peña contributed, with her presence, to raising the profile of the First Brazilian Congress of Pharmaceutical Sciences, which had over 3,000 participants. In addition, she honoured everyone with her lecture ‘Future medicines and one world.’”

Brazil’s Minister of Health Ricardo Barros (right) met with the FIP president in April
HEALTH BENEFITS FOR OUR COMMUNITIES

FACILITATING ACCESS TO MEDICINES

Universal health coverage and access to medicines have long been part of FIP’s agenda, whether the issues are pricing, a new class of medicines or policy. In May, we made pharmacists’ views on medicine shortages known at the World Health Organization Fair Pricing Forum in Amsterdam, Netherlands, hosted by the country’s Ministry of Health, Welfare and Transport. We argued that shortages can be affected by pricing and called for transparency of prices negotiated by insurers and health systems. Also in May, we were the only healthcare professionals invited to take part in the Essential Medicines and Health Products Department meeting on biosimilars to discuss how access to this group of medicines could be increased. Our participation highlighted that the right policies need to be in place and that pharmacists need to be involved to ensure uptake and execution of those policies. As a result of this meeting, the WHO announced the launch of a pilot project for prequalifying biosimilars for cancer — a step towards making them more widely available in low- and middle-income countries.

ENCOURAGING NEW CLINICAL SERVICES

Patients taking anticoagulants in Uruguay will soon be able to benefit from the greater involvement of pharmacists in their therapy, through education and monitoring. At the request for assistance from the Uruguayan Association of Chemistry and Pharmacy, FIP provided evidence of similar services from its global database of pharmacist activities, which was used at a symposium in November to enhance the role that pharmacists could play in anticoagulation management.

Ms Nora Gerpe, international affairs manager, Uruguayan Association of Chemistry and Pharmacy

“FIP’s contribution motivated us to take the first steps towards pharmacist-managed anticoagulation. The symposium acted as a catalyst to improve quality of life and health for these patients.”

Anticoagulation services are being progressed in Uruguay with the support of FIP
FIGHTING FALSIFIED MEDICINES

We believe that pharmacists, pharmaceutical scientists and educators can be a vital asset in assuring the safety of patients through their participation in the fight against fake medicines. We were pleased to assist our member organisation the National Council of Pharmacists in Cameroon, in April, with its programme of activities in this area, which included its annual October events where pharmacists give particular focus to educating the public on the dangers of counterfeit and substandard medicines. Information and guidance from FIP assisted the council to work on refreshing its campaign for 2018. FIP resources have also been used in the development of a new national project between pharmacists and the country’s Ministry of Health to protect people against falsified medicines.

Dr Prosper Hiag, president, National Council of Pharmacists in Cameroon

“Falsified medicines are a big problem in Cameroon. We think that around 30% of medicines distributed are falsified and people need to understand that these medicines kill. The information from FIP about what is being done internationally on this issue was valuable. We used it in our planning and development of activities and have disseminated FIP guidance to all pharmacies to bolster efforts.”

PROTECTING PATIENTS IN INDIA

The presence of pharmacists in pharmacies is critical for ensuring the responsible use of medicines. These pharmacists must also have autonomy to do what is best for their patients. Patient safety was at risk in India when the government proposed that unqualified people could manage pharmacies. We were quick to support the Indian Pharmaceutical Association (IPA) at the beginning of the year in opposing this proposal, providing a letter from the FIP President to the Indian Government.

Ms Manjiri Gharat, vice president, Indian Pharmaceutical Association, and chairperson, IPA community pharmacy division

“The letter from FIP to the Government of India regarding the importance of the pharmacist in health care provided huge impetus and confidence to IPA and similar organisations to take up stronger advocacy measures to ensure the mandatory presence of qualified pharmacists in pharmacies. As a consequence, the Government of India refrained from taking any decision which would have adversely impacted the pharmacy profession and patient safety.”
EDUCATION AND HUMAN RESOURCES

TALKING INVESTMENT IN EDUCATION AND WORKFORCE

Advancing investments in pharmacy education and the development of the pharmaceutical workforce was put on the agenda by FIP Education Development Team director Ian Bates at a World Health Assembly event in May. Professor Bates was invited to speak at the event, “Promoting intersectoral and coordinated actions to further invest in health and social workforce”, organised jointly by the health ministries of Argentina, France, Nepal, Nigeria, Philippines and South Africa. He highlighted the importance of developing indicators which reflect the need for the necessary resources to describe, develop and quantify the return on investment for any national economy through investment in our pharmaceutical healthcare workforce, including pharmaceutical scientists. He also discussed FIP’s commitment to workforce development and the launch of the Global Vision for Education and Workforce, the Pharmaceutical Workforce Development Goals and the Nanjing Statements. In particular, the clear alignment between the goals and the World Health Organization’s global strategies for human resources for health was presented.

Prof. Ian Bates, director, Education Development Team, FIP Education
“To have clear alignment with the World Health Organization’s human resources for health policies demonstrates our strong leadership for this critical health workforce.”

DISCUSSING WORKING CONDITIONS

It was important pharmacists were not overlooked when employer and employee unions and governments gathered to discuss improving employment and working conditions in health services at an event hosted by the International Labour Organization in April. FIP CEO Luc Besançon was at the meeting in Geneva, Switzerland, making sure this did not happen. Representing the profession at this UN agency meeting, he reminded stakeholders to consider pharmacists in the discussions and advocated for their inclusion in any UN recommendations regarding the promotion of decent work and employment in the health services sector.

PUSHING INNOVATIVE TRAINING

Training the pharmaceutical sciences workforce of the future is a vital component of the global vision for workforce development. FIP continues to advocate for the support of pharmaceutical sciences within pharmacy, in an environment where an increasing proportion of the pharmaceutical science workforce is trained outside the traditional pharmacy education pathway, for example, in engineering, biology or chemistry. At the Asian Federation for Pharmaceutical Sciences conference, Xiamen, China, in November, our scientific secretary Giovanni Pauletti emphasised the importance of welcoming innovative training pathways that provide the right mix of knowledge, skills (including real world experience, decision-making, initiative and confidence), attitudes and values.
SHARING OUR WORKFORCE DEVELOPMENT TOOLS

FIP continued with its commitment to support the effective implementation of the World Health Organization’s Global Strategy on Human Resources for Health in November, sharing its workforce transformation documents at a special side event to the Fourth Global Forum on Human Resources for Health in Dublin, Ireland. During the event, hosted by FIP Education, FIPEd project coordinator and researcher Lina Bader presented FIP’s milestone roadmap documents to policymakers, planners, practitioners, academics and researchers, explaining the methods behind their development and how they are intended to be used. The participants also engaged in roundtable discussions to share their views on the main challenges and facilitators for effective national-level implementation of FIP’s workforce development goals. We are proud to have been able to showcase these key pharmacy workforce transformation roadmap documents as an example of the key role professional organisations can play in supporting health workforce strategies.

Ms Anne Depagne-Loth, scientific officer — assessment and impact studies, National Agency for Continuing Professional Development in Healthcare — France

“First, as a scientific officer, I was impressed by the quality of the reports published by FIP, providing substantial reflection and high-quality data about education and workforce development in pharmacy all around the world. Second, as a delegate from the National Agency for Continuing Professional Development in Healthcare — France, at the Fourth Global Forum on Human Resources for Health in Dublin, I had the opportunity to appreciate through several great panel discussions the leadership of the FIP in the global movement for healthcare workforce and its convincing vision for transformative pharmacy.”

PROVIDING FREE PROFESSIONAL DEVELOPMENT

FIP’s sections expanded their professional development offering in 2017, providing 60% more webinars on 17 topics tailored to specific areas of interest and addressing local and regional needs. Among these webinars were “Falsified medicines” from the Community Pharmacy Section, “How pharmacists can support patients during Ramadan” from the Military and Emergency Pharmacy Section, “Home pharmaceutical care” from the Social and Administrative Pharmacy Section, and “Hospital pharmacy automation” run by the Hospital Pharmacy Section. Some topics were also offered in Spanish and Japanese as well as in English and we know that registrants have come from over 100 countries. As part of our service to global health, we allow any interested practitioner, anywhere in the world, to benefit from these webinars when they take place. All previous webinars are then housed on the FIP website for our members to access. Professional development resources from FIP also included a document produced by FIP’s Young Pharmacists Group, “Leading with emotional intelligence”, aimed at helping young pharmacists to learn and practise emotional intelligence skills and the International Pharmaceutical Students’ Federation.

Ms Hanadi AlSabban, discharge counselling pharmacist, King Faisal Specialist Hospital & Research Centre, Saudi Arabia

“All the webinars of the hospital pharmacy section are interesting. Thank you, FIP, for your effort in choosing such up-to-date and valuable topics.”
COLLABORATIONS AND PARTNERSHIPS

SERVING PUBLIC HEALTH BY IMMUNISATION

FIP is committed to addressing the challenge of saving lives and improving health and productivity of communities via vaccination. To mark World Immunization Week in April, FIP worked with the International Federation of Pharmaceutical Manufacturers & Associations to organise a symposium in Geneva, Switzerland, where pharmacists, the medical community, decision-makers and vaccines manufacturers discussed how influenza vaccines protect individuals and their families, as well as broader positive and economic social impacts. We also took the opportunity to extend our outreach to the public, with our CEO speaking on Radio Switzerland. This was followed in August by our Board of Pharmaceutical Practice chair Dominique Jordan participating in a round table at a meeting on adult vaccination held by the International Federation on Ageing. Mr Jordan called for governments to broaden the accessibility of vaccinations by allowing pharmacists to administer vaccines.

Mr Christian Roth, president, International Pharmaceutical Students’ Federation

“IPSF and FIP have a long-existing partnership and joint history aiming to advance our profession. It is always a great pleasure to welcome Prof. Ralph Altiere and other colleagues from FIP at our conferences to connect the current and future generations on mutual exchange and joining forces for various projects.”

Ms Paula Barbosa, manager, vaccines policy, International Federation of Pharmaceutical Manufacturers and Associations

“Influenza is a major public health concern causing up to one million deaths annually, with immunisation being the most effective measure to prevent it. Countries with pharmacy-administered influenza vaccination programmes have seen a boost in vaccine uptake, helping also build trust and confidence among patients. This symposium highlighted the opportunities for collaboration among different stakeholders, and raised awareness of the value of influenza vaccination among the Geneva audience.”

ENGAGING WITH COLLEAGUES OF THE FUTURE

Serving global health includes ensuring that our profession is ready and capable in years to come. FIP has a long history of working with the International Pharmaceutical Students’ Federation (IPSF) and this collaboration continued in 2017 with our presence at the IPSF annual conference. FIP’s Academic Pharmacy Section immediate past president Ralph Altiere was in Taipei, Taiwan, in August, supporting workshops on education and entrustable professional activities.

Mr Christian Roth, president, International Pharmaceutical Students’ Federation

“IPSF and FIP have a long-existing partnership and joint history aiming to advance our profession. It is always a great pleasure to welcome Prof. Ralph Altiere and other colleagues from FIP at our conferences to connect the current and future generations on mutual exchange and joining forces for various projects.”

Ms Paula Barbosa, manager, vaccines policy, International Federation of Pharmaceutical Manufacturers and Associations

“Influenza is a major public health concern causing up to one million deaths annually, with immunisation being the most effective measure to prevent it. Countries with pharmacy-administered influenza vaccination programmes have seen a boost in vaccine uptake, helping also build trust and confidence among patients. This symposium highlighted the opportunities for collaboration among different stakeholders, and raised awareness of the value of influenza vaccination among the Geneva audience.”
EMPOWERING NETWORKING IN SCIENCE

FIP’s Board of Pharmaceutical Sciences is proud to have been able to work with the U.S. Pharmacopeia and the FIP Foundation for Education and Research, administering a travel scholarship fund which enabled pharmacists and pharmaceutical scientists to attend the sixth Pharmaceutical Sciences World Congress in Stockholm, Sweden, in May (see p23). As a result, 20 people from around the world were able to present their research and engage with colleagues face to face.

CONTRIBUTING TO UNIVERSAL HEALTH COVERAGE

Substituting branded products with generic medicines can contribute to universal health coverage through access to more affordable medicines. Among our many contributions to the work of the World Health Organization in 2017 was a focus on generic medicines prescribing — a key strategy to contain the cost of and improve access to medicines. For generic prescribing to be effective, pharmacists must be on board. We invited the WHO to present its work around international non proprietary names, including its new project “Schools of INN” at the 77th World Congress of Pharmacy and Pharmaceutical Sciences in September (see p25). In the same month, we also endorsed a campaign by our colleagues in the Republic of Korea to encourage generic prescribing, facilitating a press briefing and arranging the presence of a WHO representative to field questions.

Dr Raffaella Balocco, group lead of the World Health Organization INN Programme

“International Nonproprietary Names (INN) protect in an invisible manner every patient on this planet. However the names would be just names without the active collaboration of all the INN stakeholders and, in particular, pharmacists. The collaboration between WHO and FIP to promote INN and generic prescription not only promotes access to medicines, but also safeguards access to quality, safe and efficacious medicines.”

DEVELOPING CAREERS IN LATIN AMERICA

FIP supported a project by the Pharmaceutical Forum of the Americas to assess the impact of online courses related to pharmacy services that the forum and the Pan-American Health Organization (PAHO) have jointly organised since 2014. Some 232 pharmacists from eight countries in Latin America — including many in management positions — have taken these courses. The financial grant from FIP, made by the Bureau in March, will be used for this evaluation work.

Dr Eduardo Savio, immediate past president, Pharmaceutical Forum of the Americas

“This initiative has been the most important sustained collaboration carried out by the forum and PAHO in the past three years. All member organisations, as well as PAHO, are very interested in knowing if we have [taken the right path], what the impact is on health systems, and what the main outcomes of these courses are.”

Scholarship beneficiaries explained what the funding meant to them in a video

FIP supported its member organisations in the Republic of Korea at a press briefing on generic prescribing
World Pharmacists Day is marked by colleagues around the globe, highlighting the impact and added value of the pharmacy profession and its role in improving health to authorities, other professions, the media and the general public. Its purpose is to encourage promotion and advocacy for the role of the pharmacist in improving health in every part of the world.

“From research to health care: Your pharmacist is at your service” was the theme for World Pharmacists Day 2017. Designated by the FIP Bureau, the theme reflected the numerous contributions the pharmacy profession makes to health, from research and development of medicines, to educating future pharmacists and pharmaceutical scientists, and providing direct care. FIP offered free campaign materials in the six official United Nations languages, and these were widely used.

World Pharmacists Day has grown each year. In its seventh year in 2017, it was celebrated through numerous activities, from rallies and free screenings to seminars and talks on television and radio stations.

Pharmacists in Solapur, Maharashtra State, India, provided people with free blood pressure monitoring and asthma tests, as well as screening for diabetic retinopathy in diabetic patients.

The Croatian Pharmaceutical Society organised its second Forum of Excellence in Pharmaceutical Care, bringing together many partners in health.

At Healthpoint Hospital, Abu Dhabi, United Arab Emirates, pharmacists educated patients on how to properly store medicines.

Students at the University of Santo Tomas, Faculty of Pharmacy, Manila, Philippines, gave lectures highlighting the World Pharmacists Day theme and encouraged people to visit their pharmacist for advice.

Pharmacists in Nigeria went on air at radio Grace FM 95.5 to talk about their roles in health care.
The city of Swedish scientist Alfred Nobel — Stockholm — was a fitting setting for the theme of FIP’s Sixth Pharmaceutical Sciences World Congress, held in May. “Future medicines for one world” brought together researchers from the fields of drug design, drug delivery and drug formulation, regulation and clinical practice, to share and collaborate on a new approach — the systems approach — to the discovery, development and clinical use of medicines.

There were 1,071 participants, including 112 speakers, from 73 countries at the congress, and 625 abstracts were presented. The congress was co-organised by the European Federation for Pharmaceutical Sciences and the Swedish Pharmaceutical Society.

Prof. Erem Bilensoy, president, European Federation for Pharmaceutical Sciences
“The experience that the European Federation for Pharmaceutical Sciences had during the co-organisation of PSWC2017 was a very pleasant and fruitful collaboration. The closing panel was an important outlook on the future of medicines and what to implement in the development of these innovative technologies so that it is possible to achieve open innovation and easy access to medicines around the globe. The impressive number, diversity and quality of presentations proved to be beneficial to delegates from academia, industry and also health and regulatory authorities.”

Prof. Meindert Danhof, congress chair, PSWC 2017
“Under the title ‘Systems approaches to drug discovery, development and clinical usage’, PSWC 2017 was a landmark for both the pharmaceutical sciences and pharmaceutical practice. Novel ‘systems therapeutics interventions’ hold the promise of curing diseases formerly considered untreatable. . . . PSWC 2017 was the first global conference to bring all disciplines in the field of systems therapeutics together. In Stockholm we laid the foundation for multidisciplinary research and collaborations on the development of future systems therapeutic interventions.”

Dr Dan Hartman, director of integrated development, Bill & Melinda Gates Foundation
“It was a pleasure to participate in the PSWC 2017 with numerous other colleagues from the Bill & Melinda Gates Foundation. There was a clear interest from the diverse attendees in the topic of global health. It was impressive to see experts from so many different areas of pharmaceutical sciences exchange ideas on how to help the world’s most impoverished populations.”

Ms Rebecka Isaksson, PhD student, department of medical chemistry, Uppsala University, Sweden
“PSWC was a wonderful opportunity to meet researchers across the field of pharmaceutical science and discuss current issues that the field is facing right now. FIP also provided us with an opportunity to arrange a pre-PSWC conference for young scientists [held] in Uppsala, Sweden.”
AWARDS

RECOGNISING INNOVATION AND BEST PRACTICES

FIP grants two awards each year to its member organisations for the best pharmacy improvement and the best health promotion work.

The 2017 Best Pharmacy Practice Improvement Programme Award went to the Royal Dutch Pharmacists Association for its campaign on counselling patients receiving a medicine for the first time. The Korean Pharmaceutical Association and pharmaSuisse (Switzerland) were the joint recipients of the Best Health Promotion Campaign Award for their campaigns on the responsible use of medicines and colorectal cancer, respectively.

Ms Lee Ae Hyung, director of appropriate drug use, Korean Pharmaceutical Association

“It was a great honour for pharmaSuisse to be the recipient of this award. It is a strong recognition of our huge investment to implement new services in pharmacy. It is important that pharmacists are recognised as key partners also in the topic of prevention.”

Ms Martine Ruggli, head of department, interprofessional collaboration, pharmaSuisse

“It was a great honour for pharmaSuisse to be the recipient of this award. It is a strong recognition of our huge investment to implement new services in pharmacy. It is important that pharmacists are recognised as key partners also in the topic of prevention.”

“Mr Gerben Klein Nulent, chairman of the Royal Dutch Pharmacists Association

“All of us at the Royal Dutch Pharmacists Association were very proud to receive the FIP 2017 Pharmacy Practice Improvement Award. The award represents international recognition for the public awareness campaign we had worked so hard to create in the Netherlands. Of course, our work is by no means done. It is imperative that we continue to show the positive impact pharmacists have in the healthcare system.”
FIP also made the following awards in 2017:

**Høst Madsen Medal**
Prof. Mitsuru Hashida (Japan)

**Distinguished Service Award**
Mr Howard Rice (Israel)

**Distinguished Practice Award**
Ms Jane Dawson (New Zealand)

**Eleven fellowships**
- Prof. Lilian Azzopardi (Malta)
- Dr Betty Chaar (Australia)
- Prof. Mahama Duwiejua (Ghana)
- Ms Kirstie Galbraith (Australia)
- Dr Walter da Silva Jorge João (Brazil)
- Prof. Takuya Kumamoto (Japan)
- Mr Luís Miguel Lourenço (Portugal)
- Dr Arijana Meštrović (Croatia)
- Mr Michael Rouse (USA)
- Mr Paul Sinclair (Australia)
- Prof. Bob Sindelar (Canada)

New FIP fellows (left to right): Lilian Azzopardi, Betty Chaar, Walter da Silva Jorge João, Mahama Duwiejua, Kirstie Galbraith, Takuya Kumamoto, Luís Miguel Lourenço, Arijana Meštrović, Michael Rouse, Paul Sinclair and Bob Sindelar
ELECTIONS AND COUNCIL DECISIONS

The FIP Council, through which all member organisations have voting rights, meets once a year. At the Council meeting in August 2017, elections were held and a number of decisions were made.

Elections
Ms Jacqueline Surugue (France), hospital pharmacist, was elected as one of eight vice presidents on the FIP Bureau (board).

Decisions
The FIP Council ratified the following Bureau appointments:
- Ms Ema Paulino as professional secretary
- Prof. William Charman as FIP Education chair

The FIP Council adopted the following policy statements:
- Control of antimicrobial resistance
- Strategic development of medicines information for the benefit of patients and users of medicines
- Role of the pharmacist in disaster management
- Pharmacy: Gateway to care
“Medicines and beyond! The soul of pharmacy” was the theme of FIP’s 77th World Congress of Pharmacy and Pharmaceutical Sciences, which was held in Seoul, Republic of Korea, in September, and co-hosted by the Korean Pharmaceutical Association and the Pharmaceutical Society of Korea.

The programme included sessions on new pharmacy practices, technological advances, healthy ageing, gene therapy and leadership. It also included a Deans Forum and a Pharmacy Technicians Symposium.

There were 2,603 participants, including 235 speakers, from 96 countries, and 583 abstracts were presented. Twelve countries accredited sessions for continuing professional development/continuing education. Participants listed the top three benefits of attending the congress as:

- “Getting the global view on pharmacy and pharmaceutical sciences.”
- “Meeting global leaders in pharmacy and pharmaceutical sciences.”
- “Advancing pharmacy in the right direction.”

Mr Chan-Hwi Cho, president, Korean Pharmaceutical Association

“It was our great pleasure to host the 2017 FIP congress in Seoul successfully through a good collaboration with FIP headquarters. The [congress] is a cornerstone on which KPA can develop further and become more globalised. [We] also had an opportunity to learn and exchange many global experiences and information on various areas in pharmacy and pharmaceutical science.”

Prof. Aree Moon, president, Pharmaceutical Society of Korea

“Hosting the 2017 FIP Seoul congress was a precious experience. The constructive and insightful opinions shared by speakers and participants made the congress a successful model for regional as well as international cooperation of all pharmacists worldwide.”

Ms Ashley Soyeon Lee, PharmD student, Ewha Women’s University, Seoul, Republic of Korea

“Being a student volunteer at the FIP world congress was a life-changing experience. I was able to interact with so many enthusiastic, like-minded participants all over the world and become aware of worldwide pharmaceutical issues. It was more than enough to broaden my horizons and trigger a passion for working in international contexts. Overall, the experience was well worth the ‘post-congress blues’ I suffered for a while.”

Neunghoo Park, Korean Minister of Health and Welfare, said that the Korean government was more than ready to accommodate proposals from the FIP congress.
PUBLICATIONS 2017

- **MEDICINES INFORMATION: STRATEGIC DEVELOPMENT** (January)
- **TRANSFORMING PHARMACY AND PHARMACEUTICAL SCIENCES EDUCATION IN THE CONTEXT OF WORKFORCE DEVELOPMENT** (May)
- **REDUCING HARM ASSOCIATED WITH DRUGS OF ABUSE: THE ROLE OF PHARMACISTS** (November)
- **TWO ISSUES OF THE INTERNATIONAL PHARMACY JOURNAL** (July and November)
- **REPORTING MEDICINES SHORTAGES: MODELS AND TACTICAL OPTIONS** (May)
- **TECHNICIANS AND PHARMACY SUPPORT WORKFORCE CADRES WORKING WITH PHARMACISTS** (February)
- **NANJING STATEMENTS ON PHARMACY AND PHARMACEUTICAL SCIENCES EDUCATION** (May)
- **PHARMACY AT A GLANCE** (September)
- **Nanjing Statements on Pharmacy and Pharmaceutical Sciences Education** (May)
- **REPORTING MEDICINES SHORTAGES: MODELS AND TACTICAL OPTIONS** (May)
- **EXCLUSIVELY AVAILABLE TO FIP MEMBER ORGANISATIONS**
- **LEADING WITH EMOTIONAL INTELLIGENCE** (March), exclusively for members of FIP’s Young Pharmacists Group
- **EXCLUSIVELY AVAILABLE TO FIP MEMBER ORGANISATIONS**
- **PHARMACY AS A GATEWAY TO CARE: HELPING PEOPLE TOWARDS BETTER HEALTH** (April)
- **PHARMACY VISION: BOARD OF PHARMACEUTICAL PRACTICE FUTURE TRENDS REPORT** (May)
- **PHARMACY: A GLOBAL OVERVIEW — WORKFORCE, MEDICINES DISTRIBUTION, PRACTICE, REGULATION AND REMUNERATION 2017** (September), exclusively for FIP member organisations
- **EXCLUSIVELY AVAILABLE TO FIP MEMBER ORGANISATIONS**
- **RESEARCH, DEVELOPMENT AND EVALUATION STRATEGIES FOR PHARMACEUTICAL EDUCATION AND THE WORKFORCE: A GLOBAL REPORT** (September)
- **EXCLUSIVELY AVAILABLE TO FIP MEMBER ORGANISATIONS**
- **PHARMACEUTICAL SCIENCES WORLD CONGRESS VIDEO SERIES** (nine interviews) and abstracts
- **WORLD CONGRESS OF PHARMACY AND PHARMACEUTICAL SCIENCES VIDEO SERIES** (nine interviews) and abstracts
- **Maria Alonso, professor of biopharmaceutics and pharmaceutical technology, University of Santiago de Compostela, Spain, on women in pharmaceutical sciences**
- **Mariet Eksteen, module coordinator, North-West University, South Africa, on team based learning in pharmacy education**
WORK IN PROGRESS

DURING 2017, FIP ALSO WORKED ON THE FOLLOWING AREAS:

FIP STRATEGIC PLAN
Work began on the development of a strategic plan that communicates FIP’s future goals and determines the actions needed to achieve them. In 2017, priorities were set with the assistance of the FIP Council and individual FIP members who participated in an open consultation. We have started to identify where we need to focus our energy and resources and strengthen operations in order to adapt to a changing environment.

WOMEN AND THE RESPONSIBLE USE OF MEDICINES
We gathered evidence on how pharmacists can contribute as agents of women’s empowerment through supporting and promoting their education, and providing them with the information they need to use medicines responsibly. Our findings are due to be released in a report in 2018.

HARM REDUCTION
Subsequent to the publication of our reference paper “Reducing harm associated with drugs of abuse: The role of pharmacists”, work began on creating a political message on this topic with a new FIP statement of policy to be put before the FIP Council in 2018.

NON-COMMUNICABLE DISEASES
The FIP Working Group on Non-communicable Diseases (NCDs) is developing a reference paper on the role and impact of community pharmacists in NCDs through prevention, screening, referral and management activities. This will offer a basis of global evidence and best practices to advocate to national and international policy-making bodies for an expanded role for pharmacists in NCD management, particularly in the cardiovascular diseases, diabetes, asthma, chronic obstructive pulmonary disease and cancer.

SUPPLY CHAIN
FIP’s Board of Pharmaceutical Practice set up a working group to provide an overview of the value that pharmacists add to the pharmaceutical supply chain. A report, due to be published in 2018, will aim to provide a global picture, taking the scarcity of pharmacists in many settings into consideration, and clearly identifying where the competencies of pharmacists are best used and most needed.
FUTURE CONGRESSES
Work is under way for our annual congress in Glasgow, UK (2–6 September 2018, “Pharmacy: Transforming outcomes”) as well as our 2019 congress which will be held in Abu Dhabi, United Arab Emirates.

GLOBAL PHARMACY OBSERVATORY
We started work on a new online pharmacy-related information hub that can be used by member organisations to inform advocacy work, policy development, decision-making, workforce intelligence and the advancement of pharmaceutical practice, sciences and education. Under the guidance of an advisory committee of FIP member organisations and pharmacy and health workforce experts, we have been working towards developing a user-friendly platform that will be a valuable source of data and knowledge.

GENDER EQUITY AND DIVERSITY
FIP is working with the WHO Gender Equity Hub to address gender inequities and biases in the pharmacy and pharmaceutical sciences workforce. We are working on generating data and evidence on gender equity in global health and pharmacy. We will continue working on evidence and policy recommendations on women in pharmacy and pharmaceutical sciences to enable the implementation of gender equity and diversity policies in line with Pharmaceutical Workforce Development Goal 10.

WORKFORCE INTELLIGENCE
Workforce intelligence is one of the FIP’s Pharmaceutical Workforce Development Goals. It provides strategic information to support workforce planning and expanding access to health care delivery. Strengthening workforce data monitoring and analysis is key to implementing the World Health Organization Global Strategy on Human Resources for Health and achieving universal health coverage. Building on previous evidence and reports, FIP Education is working towards the launch of a global report on Workforce Intelligence Trends in 2018.

EDUCATION AND WORKFORCE DEVELOPMENT
Following the launch of the Global Vision for Education, Nanjing Statements on pharmacy education and the Pharmaceutical Workforce Development Goals (PWDGs), FIP Education is working to progress the transformation of pharmaceutical education and workforce around the world. We are developing implementation toolkits for the PWDGs and to guide FIP members in their workforce development strategies.
PATIENT SAFETY
FIP began the process to establish a working group on patient safety. Pharmacists are in a unique position to address the challenges related to medicines use. They are becoming more involved in both therapeutic decisions and advocacy of stewardship programmes. The working group will be tasked with producing a reference document on the role of pharmacists in patient safety and to advise on the implementation of safe medication practices in different settings.

WORLD HEALTH ORGANIZATION DOCUMENTS
In 2017, we reviewed and provided input into 16 draft WHO documents, including the WHO draft guidance on testing of “suspect” substandard and falsified medicines and collaborative procedure in the assessment and accelerated national registration of pharmaceutical products approved by stringent regulatory authorities. Our contribution to these yet-to-be-published documents will continue.

PLAN FOR PHARMACEUTICAL SCIENCES BOARD
All FIP’s special interest groups and predominantly scientific member organisations contributed to a new strategic plan for the Board of Pharmaceutical Sciences, intended to identify opportunities to improve the pharmacy practice through science and education and vice versa. This was published in February 2018.

ADHERENCE IN ELDERLY PATIENTS
In collaboration with the University of Sydney and with contributions from FIP member organisations, we are working on a report that will evaluate pharmacy interventions and programmes that are intended to enhance medication adherence in the elderly, with reference to their effectiveness. This report will serve as a benchmark to support the advocacy activities of FIP and our member organisations towards governments and other agencies on this important role of pharmacists.
# FINANCES

## BALANCE SHEET AT 31 DECEMBER 2017

After appropriation of the results for 2017

Expressed in EURO

<table>
<thead>
<tr>
<th></th>
<th>31 DECEMBER 2017</th>
<th>31 DECEMBER 2016</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Intangible fixed assets</strong></td>
<td>53 343</td>
<td>591 373</td>
</tr>
<tr>
<td><strong>FIXED ASSETS</strong></td>
<td>566 814</td>
<td>591 373</td>
</tr>
<tr>
<td><strong>CURRENT ASSETS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Debtors, prepayments and accrued income</td>
<td>353 302</td>
<td>521 951</td>
</tr>
<tr>
<td>Cash at bank and in hand</td>
<td>2 329 123</td>
<td>2 173 931</td>
</tr>
<tr>
<td><strong>TOTAL CURRENT ASSETS</strong></td>
<td>2 682 426</td>
<td>2 695 882</td>
</tr>
<tr>
<td><strong>TOTAL ASSETS</strong></td>
<td>3 302 583</td>
<td>3 287 255</td>
</tr>
<tr>
<td><strong>CAPITAL AND RESERVES</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Capital FIP</td>
<td>1 091 163</td>
<td>1 286 463</td>
</tr>
<tr>
<td>Capital FIP sections</td>
<td>592 653</td>
<td>540 184</td>
</tr>
<tr>
<td>Congress reserve</td>
<td>650 000</td>
<td>650 000</td>
</tr>
<tr>
<td>Board of Pharmaceutical Practice reserve</td>
<td>107 523</td>
<td>97 635</td>
</tr>
<tr>
<td>Board of Pharmaceutical Sciences reserve</td>
<td>132 407</td>
<td>131 442</td>
</tr>
<tr>
<td>Reserve HIV/AIDS</td>
<td></td>
<td>5 000</td>
</tr>
<tr>
<td>Reserve FIP/AIDS</td>
<td>181 724</td>
<td>131 751</td>
</tr>
<tr>
<td><strong>TOTAL CAPITAL AND RESERVES</strong></td>
<td>2 755 470</td>
<td>2 842 476</td>
</tr>
<tr>
<td><strong>PROVISIONS</strong></td>
<td>23 057</td>
<td>26 291</td>
</tr>
<tr>
<td><strong>CURRENT LIABILITIES</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>TOTAL CAPITAL AND RESERVES AND LIABILITIES</strong></td>
<td>3 302 583</td>
<td>3 287 255</td>
</tr>
</tbody>
</table>
## INCOME

<table>
<thead>
<tr>
<th>Description</th>
<th>ACTUALS 2017</th>
<th>BUDGET 2017</th>
<th>BUDGET vs ACTUALS</th>
<th>ACTUALS 2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>Membership fees</td>
<td>1 169 135</td>
<td>1 087 000</td>
<td>82 135</td>
<td>1 130 397</td>
</tr>
<tr>
<td>Congress revenues</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- FIP annual congress</td>
<td>1 113 116</td>
<td>1 700 000</td>
<td>(386 884)</td>
<td>1 032 007</td>
</tr>
<tr>
<td>- PSWC 2017 congress</td>
<td>609 714</td>
<td>990 000</td>
<td>(380 286)</td>
<td></td>
</tr>
<tr>
<td>Publications</td>
<td></td>
<td></td>
<td>(4 000)</td>
<td>522</td>
</tr>
<tr>
<td>Other income BPS</td>
<td>3 880</td>
<td></td>
<td>3 880</td>
<td>1 048</td>
</tr>
<tr>
<td>Section income</td>
<td>103 375</td>
<td>100 000</td>
<td>3 375</td>
<td>69 250</td>
</tr>
<tr>
<td>FIPEd income</td>
<td>138 423</td>
<td>180 000</td>
<td>(41 577)</td>
<td>199 213</td>
</tr>
<tr>
<td>WHPA Counterfeit Campaign income</td>
<td></td>
<td></td>
<td></td>
<td>31 802</td>
</tr>
<tr>
<td>Other income</td>
<td>13 281</td>
<td>30 000</td>
<td>(16 719)</td>
<td>7 628</td>
</tr>
<tr>
<td><strong>TOTAL INCOME</strong></td>
<td><strong>3 350 924</strong></td>
<td><strong>4 091 000</strong></td>
<td><strong>(740 076)</strong></td>
<td><strong>2 471 867</strong></td>
</tr>
</tbody>
</table>

## EXPENSES

<table>
<thead>
<tr>
<th>Description</th>
<th>ACTUALS 2017</th>
<th>BUDGET 2017</th>
<th>BUDGET vs ACTUALS</th>
<th>ACTUALS 2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>Membership costs</td>
<td>190 830</td>
<td>100 000</td>
<td>90 830</td>
<td>131 831</td>
</tr>
<tr>
<td>Personnel costs</td>
<td>996 609</td>
<td>960 000</td>
<td>36 609</td>
<td>924 125</td>
</tr>
<tr>
<td>Office costs</td>
<td>166 001</td>
<td>150 000</td>
<td>16 001</td>
<td>161 479</td>
</tr>
<tr>
<td>Meeting costs</td>
<td>71 202</td>
<td>136 000</td>
<td>(64 798)</td>
<td>66 293</td>
</tr>
<tr>
<td>Travel expenses external representation</td>
<td>36 830</td>
<td>50 000</td>
<td>(13 170)</td>
<td>49 463</td>
</tr>
<tr>
<td>Strategic plan</td>
<td>42 884</td>
<td></td>
<td>42 884</td>
<td></td>
</tr>
<tr>
<td>Website and IT</td>
<td>110 212</td>
<td>170 000</td>
<td>(59 788)</td>
<td>66 178</td>
</tr>
<tr>
<td>Depreciation of fixed assets</td>
<td>27 727</td>
<td>25 000</td>
<td>2 727</td>
<td>23 735</td>
</tr>
<tr>
<td>Other (special) projects</td>
<td>17 246</td>
<td>5 000</td>
<td>12 246</td>
<td>18 075</td>
</tr>
<tr>
<td>FIP congress costs</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- FIP annual congress</td>
<td>801 271</td>
<td>1 100 000</td>
<td>(298 729)</td>
<td>828 708</td>
</tr>
<tr>
<td>- PSWC 2017 congress</td>
<td>620 232</td>
<td>975 000</td>
<td>(354 768)</td>
<td></td>
</tr>
<tr>
<td>Publications</td>
<td>36 204</td>
<td>50 000</td>
<td>(13 796)</td>
<td>40 694</td>
</tr>
<tr>
<td>Subventions</td>
<td>25 084</td>
<td>32 000</td>
<td>(6 916)</td>
<td>23 707</td>
</tr>
<tr>
<td>Expenses BPP</td>
<td>88 112</td>
<td>99 000</td>
<td>(10 888)</td>
<td>78 219</td>
</tr>
<tr>
<td>Expenses BPS</td>
<td>40 915</td>
<td>63 000</td>
<td>(22 085)</td>
<td>54 657</td>
</tr>
<tr>
<td>Sections' operating costs</td>
<td>50 906</td>
<td>100 000</td>
<td>(49 094)</td>
<td>73 072</td>
</tr>
<tr>
<td>FIPEd expenses</td>
<td>88 450</td>
<td>200 000</td>
<td>(111 550)</td>
<td>132 922</td>
</tr>
<tr>
<td>Building Maintenance Fund</td>
<td>15 000</td>
<td>15 000</td>
<td>15 000</td>
<td>15 000</td>
</tr>
<tr>
<td>WHPA Counterfeit Campaign</td>
<td></td>
<td></td>
<td>31 802</td>
<td></td>
</tr>
<tr>
<td>Business development</td>
<td>435</td>
<td>20 000</td>
<td>(19 565)</td>
<td>8 459</td>
</tr>
<tr>
<td><strong>TOTAL EXPENSES</strong></td>
<td><strong>3 426 151</strong></td>
<td><strong>4 250 000</strong></td>
<td><strong>(823 849)</strong></td>
<td><strong>2 732 418</strong></td>
</tr>
</tbody>
</table>

## OPERATING RESULT

<table>
<thead>
<tr>
<th>Description</th>
<th>ACTUALS 2017</th>
<th>BUDGET 2017</th>
<th>BUDGET vs ACTUALS</th>
<th>ACTUALS 2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>Financial result</td>
<td>(11 779)</td>
<td>4 000</td>
<td>(15 779)</td>
<td>(2 483)</td>
</tr>
<tr>
<td><strong>NET RESULT BEFORE APPROPRIATION</strong></td>
<td><strong>(87 006)</strong></td>
<td><strong>(155 000)</strong></td>
<td><strong>67 994</strong></td>
<td><strong>(263 035)</strong></td>
</tr>
</tbody>
</table>

## Appropriation of the results

<table>
<thead>
<tr>
<th>Description</th>
<th>ACTUALS 2017</th>
<th>BUDGET 2017</th>
<th>BUDGET vs ACTUALS</th>
<th>ACTUALS 2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>BPP general reserves</td>
<td>9 888</td>
<td>(9 000)</td>
<td>18 888</td>
<td>20 781</td>
</tr>
<tr>
<td>BPS general reserves</td>
<td>965</td>
<td>12 250</td>
<td>(11 285)</td>
<td>(15 609)</td>
</tr>
<tr>
<td>Section capital</td>
<td>52 469</td>
<td></td>
<td>52 469</td>
<td>(3 822)</td>
</tr>
<tr>
<td>Reserve FIPEd</td>
<td>49 973</td>
<td></td>
<td>49 973</td>
<td>66 291</td>
</tr>
<tr>
<td>Reserve HIV/AIDS</td>
<td>(5 000)</td>
<td></td>
<td>(5 000)</td>
<td>(5 000)</td>
</tr>
<tr>
<td>FIP capital</td>
<td>(195 300)</td>
<td>(158 250)</td>
<td>(37 050)</td>
<td>(325 676)</td>
</tr>
<tr>
<td><strong>TOTAL APPROPRIATION</strong></td>
<td><strong>(87 006)</strong></td>
<td><strong>(155 000)</strong></td>
<td><strong>67 994</strong></td>
<td><strong>(263 035)</strong></td>
</tr>
</tbody>
</table>